bioRxiv ScienceSearch

bioRxiv · 10.1101/804815

Dillenia indica fruit extract has Glucose and Cholesterol Lowering effects

Abstract

BackgroundDillenia indica (D. indica) can suppress carbohydrates hydrolysis by inhibiting -amylase and -glucosidase. However, there is a lack of understanding of its therapeutic potential as an antidiabetic and anti-hyperlipidemic agent. Methods and findingsType 2 diabetes (T2D) was induced by a single intraperitoneal injection of Streptozotocin (STZ; 90mg/kg) and hyperlipidemia by feeding with 1% cholesterol, 5% coconut oil and 5% cow fat diet. Administration of D. indica extracts in water for four weeks triggered a significant (p[≤]0.05) reduction in fasting serum glucose (FSG) levels with concomitant improvement in serum insulin levels. Both the water- and ethanol-extract of D. indica treated groups showed significant (p[≤]0.01) reduction in total cholesterol levels by 25% and 19%, respectively. HDL-cholesterol was also augmented (by 14%) in ethanol-extract treated group. Liver glycogen content was higher in the water-extract treated group. Histopathological examination revealed that there was no tubular epithelial cell degeneration or necrosis in the renal tissues or hepatocyte degeneration and sinusoidal dilation in liver tissues in animals that received the water-extract. On the other hand, consumption of D. indica extract with 1% cholesterol, 5% coconut oil diet or with a 5% cow fat diet for 14 days significantly reduced serum cholesterol levels in group-lll (60[->]45 mg/dl; p[≥]0.05) and -IV (85[->]66 mg/dl; p[≥]0.05) hypercholesterolemic model rats. D. indica fruit extract also reduced serum TG levels (Group-III: 87[->]65 mg/dl; Group-IV: 40[->]90 mg/dl; p[≥]0.05). Interestingly, treatment with D. indica prevented a reduction in serum HDL levels in those hypercholesterolemic model rats. Serum LDL levels were significantly lower in group-III (47[->]39 mg/dl; p[≥]0.05) and group-IV (57[->]44 mg/dl; p[≥]0.05) hypercholesterolemic model rats after D. indica treatment. ConclusionD. indica fruit ameliorates FSG, insulin secretion, glycogen synthesis, and serum lipid profile. Therefore, D. indica fruit can be a potential therapeutic agent for diabetic and hyperlipidemia. Graphical AbstractExtract of D. indica in water reduces FSG, serum insulin levels, and ameliorates the serum lipid profile in diabetic model rats without any adverse effects on kidney and liver tissues. Extract of D. indica in ethanol significantly reduces serum cholesterol, TG, LDL with no reduction in HDL levels in hyper-lipidemic model rats. HighlightsO_LID. indica fruit extracts diminished fasting serum glucose (FSG) levels in STZ-induced type 2 diabetic model rats C_LIO_LID. indica fruit extracts boosted insulin secretion C_LIO_LID. indica fruit extracts showed no toxic effects on the kidney and the liver functions C_LIO_LIExtract in water was more effective in reducing FSG levels than extract in ethanol C_LIO_LIChronic consumption of 1% cholesterol, 5% coconut oil and 5% cow fat diet was sufficient to make the rat hypercholesterolemic C_LIO_LID. indica fruit extract has the potential to reduce serum cholesterol, TG, LDL with prevention in reduction in serum HDL levels. C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

KHAN, S., Bhowmik, A., Rhaman, S. B., Gan, S. H., Rokeya, B.. 2019-10-14. Dillenia indica fruit extract has Glucose and Cholesterol Lowering effects. https://doi.org/10.1101/804815

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology

Pharmacological complementation remedies an inborn error of lipid metabolism

X-linked adrenoleukodystrophy (X-ALD) is a rare, genetic disease in which increased very long chain fatty acids (VLCFAs) in the central nervous system (CNS) cause demyelination and axonal degeneration, leading to severe neurological deficits. Sobetirome, a potent thyroid hormone agonist, has been shown to lower VLCFA levels in the periphery and CNS. In this study, two pharmacological strategies for enhancing the effects of thyromimetics were tested in Abcd1 KO mice, a murine model that has the same inborn error in metabolism as X-ALD patients. First, a sobetirome prodrug (Sob-AM2) with increased CNS penetration lowered CNS VLCFAs more potently than sobetirome, and was better tolerated with lower peripheral exposure, but was unable to unable to break the efficacy threshold of CNS VLCFA lowering in Abcd1 KO mice. Second, co-administration of thyroid hormone with sobetirome enhanced VLCFA lowering in the periphery compared to sobetirome alone but did not produce greater lowering in the CNS. These data suggest that the extent of CNS VLCFA lowering in Abcd1 KO mice is limited by a mechanistic threshold related to slow turnover kinetics, potentially related to the lack of frank X-ALD disease in this model. However, Sob-AM2 has improved potency at correcting the lipid abnormality associated with X-ALD in the CNS with better tolerance than the parent drug sobetirome.

pharmacology and toxicology